3,5-Dimethylphenylboronic acid

We are 3,5-Dimethylphenylboronic acid CAS:172975-69-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Product Name: 3,5-Dimethylphenylboronic acid
Other Name:
3,5-Dimethylphenylboronic acid
3,5-Dimethylbenzeneboronic Acid
(3,5-dimethylphenyl)boronic acid
m-Xylene-5-boronic Acid
3,5-Dimethylphenylboron
CAS No: 172975-69-8
MF: C8H11BO2
MW: 149.98300
Density: 1.07 g/cm3
Boiling point: 312.7ºC at 760 mmHg
Melting point: 261-265 °C(lit.)
Flash point: 142.9ºC
UN Number: Not dangerous goods.
Transport hazard class: Not dangerous goods.
Packing group: Not dangerous goods.
 
Specification
Appearance: White powder
Assay: ≥98.0%
Water: ≤0.50%
 
Application
Be used as pharmaceutical intermediate.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

3,5-Dimethylphenylboronic acid


Related News: With the speeding up of review and approval, the number of approved innovative drugs in China is about to usher in a year of blowout.Ácido 2-bromovalerico CAS:584-93-0 With the speeding up of review and approval, the number of approved innovative drugs in China is about to usher in a year of blowout.2,4-Dichloro-1-(2-propynyloxy)benzene CAS:17061-90-4 “This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment,” Mankind Pharma Director of Marketing Sanjay Koul said in a statement.(S)-3-Acetylthio-2-methylpropionyl-L-proline CAS:64838-55-7 “This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment,” Mankind Pharma Director of Marketing Sanjay Koul said in a statement.”This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment,” Mankind Pharma Director of Marketing Sanjay Koul said in a statement.

Related Products
Product Name
4-Pyridazinecarboxylic acid View Details
2′-Deoxyadenosine-5′-monophosphate disodium salt View Details
(1S,3S,5S)-2-Azabicyclo[3.1.0]hexane-3-carboxamide methanesulfonate View Details
2-(Trifluoromethyl)acrylic acid manufacturer Dodecyl 2-methylacrylate manufacturer N-(2-Nitrophenyl)-3-oxobutanamide manufacturer 1-Bromopyrene manufacturer 4-Bromo-2,3-difluorophenol manufacturer